Novosom Takes Option to License Isis Antisense Drugs
Novosom this week said it has acquired an exclusive six-month option to license antisense inhibitors targeting the CD40 membrane protein for all indications from Isis Pharmaceuticals.
“CD40 is a validated target for both inflammatory diseases and B-cell cancers,” Novosom said, adding that it would use the antisense drugs to target indications including Crohn's disease, transplants, rheumatoid arthritis, cancer, and multiple sclerosis.
The license will give Novosom rights to CD40, as well as oligonucleotides targeting CD40 and incorporating Isis' second-generation antisense chemistry. In exchange, Isis will receive an upfront exercise fee, milestone payments, and royalties.
Rosetta to Present Cancer Dx Development Data at AACR
Rosetta Genomics this week said it will present updated results on its lead diagnostics program for cancer of unknown primary origin at the annual meeting of the American Association for Cancer Research in Los Angeles later this month.
The data will be presented in a poster entitled, "MicroRNA Signature for Identification of Tumor Origin" by Nitzan Rosenfeld, team leader of computational biology at Rosetta.